MSCs Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma

Published in
on
Michael Chastkofsky, Katarzyna C. Pituch, Hiroaki Katagi, Liliana Ilut, Ting Xiao, Yu Han, Adam M. Sonabend, David T. Curiel, Erin R. Bonner, Javad Nazarian, Craig Horbinski, Charles D. James, Amanda M. Saratsis, Rintaro Hashizume, Maciej S. Lesniak, Irina V. Balyasnikova
image_2021-09-02_075301.png

Abstract

Diffuse intrinsic pontine glioma (DIPG) is among the deadliest of pediatric brain tumors. Radiation therapy is the standard of care treatment for DIPG, but offers only transient relief of symptoms for DIPG patients without providing significant survival benefit. Oncolytic virotherapy (OV) is an anticancer treatment that has been investigated for treating various types of brain tumors. Here, we have explored the use of mesenchymal stem cells (MSC) for OV delivery and evaluated treatment efficacy using preclinical models of DIPG. Our results show that DIPG cells and tumors exhibit robust expression of cell surface proteins that are important for OV entry, and that MSCs loaded with OV disseminate within and release OV throughout the tumor in mice bearing DIPG brainstem xenografts. When combining administration of OV-loaded MSCs with radiotherapy, mice bearing brainstem DIPG xenografts experience a significant survival benefit, relative to that conferred by either therapy alone (p<0.0001). Our results support further preclinical investigation of cell-based OV therapy with radiation for potential translation in treating DIPG patients.

Acknowledgements

This work was supported by NIH R01NS087990 and P50CA221747 SPORE for Translational Approaches to Brain Cancer. We are also grateful to the Nora Redman Endowment Fund of the Community Foundation of Louisville, and to the Isabella Kerr Molina Foundation for generous gifts to support the study.